STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Amerikanska Vertex Pharmaceuticals f\u00f6rv\u00e4rvar Crinetics Pharmaceuticals f\u00f6r 85 dollar per aktie kontant motsvarande ett totalt b\u00f6rsv\u00e4rde p\u00e5 10 miljarder dollar eller cirka 8,8 miljarder netto beaktat f\u00f6r bed\u00f6md kassa som f\u00f6rv\u00e4rvas.<\/p>\n
Det framg\u00e5r av ett pressmeddelande.<\/p>\n
Styrelserna i b\u00e5de Vertex och Crinetics har godk\u00e4nt aff\u00e4ren som v\u00e4ntas komma att slutf\u00f6ras under det tredje kvartalet 2026.<\/p>\n
De f\u00f6rv\u00e4rvade tillg\u00e5ngarna uppges tillf\u00f6ra \u00f6ver 5 miljarder dollar i toppf\u00f6rs\u00e4ljningspotential. F\u00f6rv\u00e4rvet v\u00e4ntas bidra till att Vertex kan n\u00e5 en varaktig tillv\u00e4xt p\u00e5 en dubbelsiffrig niv\u00e5 samt industriledande r\u00f6relsemarginal. Aff\u00e4ren v\u00e4ntas bidra positivt till bolagets justerade r\u00f6relseresultat under 2029.<\/p>\n
Genom f\u00f6rv\u00e4rvet f\u00e5r Vertex tillg\u00e5ng till l\u00e4kemedlet Palsonify vid behandling av den s\u00e4llsynta sjukdomen akromegali. Inom denna indikation \u00e4r \u00e4ven svenska Camurus verksamma med CAM2029 som genomg\u00e5r en marknadsregistreringsprocess hos den amerikanska l\u00e4kemedelsmyndigheten FDA.<\/p>\n
I forskningsportf\u00f6ljen hos Crinetics finns \u00e4ven l\u00e4kemedelskandidaten atumelnant i fas 3 vid behandling av kongenital binjurebarkshyperplasi, en medf\u00f6dd f\u00f6rstoring av binjurebarken.<\/p>\n
Magnus Bernet +46 8 5191 7953<\/p>\n
Nyhetsbyr\u00e5n Direkt<\/p>\n","protected":false},"excerpt":{"rendered":"STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Amerikanska Vertex Pharmaceuticals f\u00f6rv\u00e4rvar Crinetics Pharmaceuticals f\u00f6r 85 dollar per aktie kontant motsvarande ett totalt…\n","protected":false},"author":2,"featured_media":299200,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[68],"tags":[6602,34,111,110,31,33,32,30],"class_list":["post-299199","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sport","tag-camurus","tag-se","tag-sport","tag-sports","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116882225710706994","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/299199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=299199"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/299199\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/299200"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=299199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=299199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=299199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}